NATURA-BISSÉ
22.11.2023 10:01:38 CET | Business Wire | Press release
Natura Bissé & Arch Amenities Group Europe have announced a formal collaboration to increase their collective presence in the luxury spa sector across the EU and the United Kingdom. The agreement fosters strategic and complementary growth opportunities for both brands, which will reference each other, capitalizing on the well-established reputation of the Natura Bissé brand, its professional and retail skincare products and services and Arch Amenities Group’s experience in managing and operating pre-eminent luxury wellness centers and spas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231122952800/en/
Barry Goldstein, CEO Arch Amenities Group (Photo: Natura Bissé)
The Spanish skincare firm, Natura Bissé, currently has a presence in more than 450 spa hotels around the world—35% of which are located in Europe—and is set to close the year with a total revenue of 100 million euros. With its headquarters in Barcelona, 82% of the company’s sales are recorded abroad, with the Unites States and China being its primary markets, followed by Spain. Over the next 3 years, Europe will become the company’s strategic focus with the aim of doubling its multi-channel presence in this region.
For its part, Arch Amenities Group and its 3800 employees currently manage over 430 properties around the world. Private clubs, fitness centers, commercial and residential spaces and, of course, hotels place their trust in the Group’s extensive experience. Among the hotel groups in their portfolio of clients are big names like Waldorf Astoria, Four Seasons and The Ritz-Carlton, who are also partners of Natura Bissé across the world.
Natura Bissé has been part of Arch Amenities Group’s Preferred Vendor Program since early 2023, connecting the Natura Bissé product suite to a host of renowned U.S.-based spas and wellness spaces such as the Eden Roc Miami Beach Resort or the Waldorf Astoria Washington DC.
Today this partnership adopts a new character as a “non-exclusive strategic agreement” in Europe, at a time when the hospitality sector is seeing increased demand for elevated wellness experiences. Proof of this comes from data in a recent report from the Global Wellness Institute, which highlights consistent 12% annual growth in the wellbeing market since 2020 and forecasts a further 52% growth by 2027.
“This strategic agreement represents a step-change in the way both leading brands address the changing needs of the European market and reinforces our collective commitment to offer unlimited innovation, inspiration as a pillar of growth and bespoke agile solutions. That is why I’m convinced that our collaboration with Arch Amenities Group Europe will allow us to expand our presence in first-class spas and wellbeing centers,” says Verónica Fisas, CEO at Natura Bissé Group.
“Partnering with Natura Bissé in Europe to develop spas is an ideal fit for Arch as we grow our presence in Europe. As one of the most celebrated luxury skincare brands in the world, our strategic collaboration with Natura Bissé allows us to extend our proven expertise in developing and managing luxury wellness spaces to bring guests an unparalleled experience powered by great products, outstanding hospitality and elevated service,” says Barry Goldstein, CEO at Arch Amenities Group.
ABOUT ARCH AMENITIES GROUP
Arch Amenities Group, based in Rockville, Maryland, is a leading provider of hospitality management and consulting services for commercial and residential properties, hotels, spas and private clubs and recreation spaces worldwide. Arch provides daily management services as well as feasibility studies, planning and design consultancy as well as recruiting, pre-opening and sustaining strategy and support. Arch is a portfolio company of private equity firm CI Capital Partners.
ABOUT NATURA BISSÉ
Natura Bissé is a globally renowned luxury skincare company. Founded in Barcelona in 1979, Natura Bissé fuses pioneering technology with the most delicate human touch in order to listen and adapt to the differing needs of each and every client.
The constant pursuit of excellence has earned Natura Bissé numerous awards, notably recognition for being the “World’s Best Spa Brand” for four consecutive years (2018-2021).
With presence in 40 countries, Natura Bissé continues to expand around the world throughout the most distinguished luxury retailers and best-in-class spas.
In 2008 the brand helped establish the Ricardo Fisas Natura Bissé Foundation to contribute to the well-being of people in vulnerable situations. To support the Foundation’s initiatives, Natura Bissé has three fundraising lines of hotel toiletries.
Images available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122952800/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom